** Shares of drugmaker BioCryst Pharmaceuticals BCRX.O fall 2% to $7.24
** BCRX on Monday filed lawsuit against Annora Pharma and other companies for patent infringement, according to SEC filing
** BCRX is seeking to stop the companies from making generic version of its rare genetic drug, Orladeyo, and delay U.S. FDA approval until patents expire
** Annora claims the three patents that expire in 2039 are invalid, unenforceable and/or won't be infringed by their generic product
** Annora did not immediately respond to Reuters' request for comment
** BCRX gained ~24% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.